Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu R, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2.
Zhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis. Biosci Trends. 2015;9:289–98.
Article CAS PubMed Google Scholar
Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913–21.
Article CAS PubMed Google Scholar
Gaba R. Planning arteriography for Yttrium-90 microsphere radioembolization. Semin Interv Radiol. 2015;32:428–38.
Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, et al. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90 Y-microsphere selective internal radiation treatment. J Nucl Med. 2010;51:1206–12.
Padia SA, Lewandowski RJ, Johnson GE, Sze D, Wart T, Gaba R, et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol. 2017;28:1–15.
Bester L, Meteling B, Pocock N, Pavlakis N, Chua T, Saxena A, et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol. 2012;23:96–105.
Collins J, Salem R. Hepatic radioembolization complicated by gastrointestinal ulceration. Semin Intervent Radiol. 2011;28:240–5.
Article PubMed PubMed Central Google Scholar
Kallini JR, Gabr A, Thorlund K, Balijepalli C, Ayres D, Katers S, et al. Comparison of the adverse event profile of TheraSphere® with SIR-Spheres® for the treatment of unresectable hepatocellular carcinoma: a systematic review. Cardiovasc Intervent Radiol. 2017;40:1033–43.
Dezarn WA, Cessna JT, DeWerd LA, Feng W, Gates V, Halama J, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90 Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011;38:4824–45.
Wright GP, Marsh JW, Varma MK, Doherty MG, Bartlett DL, Chung MH. Liver resection after selective internal radiation therapy with Yttrium-90 is safe and feasible: a bi-institutional analysis. Ann Surg Oncol. 2017;24:906–13.
Gabr A, Abouchaleh N, Ali R, Baker T, Caicedo J, Katariya N, et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29:1502–10.
Gates VL, Hickey R, Marshall K, Williams M, Salzig K, Lewandowski R, et al. Gastric injury from Y90 to left hepatic lobe tumors adjacent to the stomach: fact or fiction? Eur J Nucl Med Mol Imaging. 2015;42:2038–44.
South CD, Meyer MM, Meis G, Kim EY, Thomas FB, et al. Yttrium-90 microsphere induced gastrointestinal tract ulceration. World Journal of Surgical Oncology. 2008;6:93.
Article PubMed PubMed Central Google Scholar
Yim SY, Kim JD, Jung JY, Kim CH, Seo YS, et al. Gastrectomy for the treatment of refractory gastric ulceration after radioembolization with 90 Y microspheres. Clin Metab Hepatol. 2014;20:300–5.
Nuclear Regulatory Commission. Title 10—energy, Chapter I—Nuclear Regulatory Commission, Part 35—medical use of byproduct material, Subpart E—radiopharmaceuticals for use in diagnostic nuclear medicine procedures. https://www.nrc.gov/reading-rm/doc-collections/cfr/part035/part035-3045.html. Accessed [8/6/2023].
N.R.P.B, H.M.S.O. Recommendations of the International Commission on Radiological Protection (1977) ICRP Publication 26.; 1977.
Comments (0)